Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
DEXAMETHASONE vs ACETASOL HC
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.
Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.
Adrenal insufficiency,Inflammatory conditions,Allergic disorders,Autoimmune diseases,Cerebral edema,COVID-19 treatment (off-label),Multiple myeloma (combination therapy),Nausea/vomiting (chemotherapy-induced)
Treatment of superficial bacterial infections of the external auditory canal (swimmer's ear),Treatment of fungal infections of the external ear
0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.
5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.
Terminal elimination half-life 3-4 hours; clinically, duration of HPA suppression may exceed 24 hours due to prolonged receptor binding.
Hydrocortisone has a terminal elimination half-life of approximately 1.5-2 hours. Acetic acid has a half-life of minutes due to rapid metabolism. Clinical context: dosing interval is typically 3-4 times daily for otic use.
Primarily hepatic via CYP3A4; also metabolized by 11β-HSD2 in peripheral tissues.
Not extensively metabolized; undergoes minimal hepatic metabolism.
Primarily renal (65-80% as unchanged drug); minor biliary/fecal (<10%).
Acetasol HC is a combination product containing hydrocortisone and acetic acid. Hydrocortisone is primarily metabolized in the liver and excreted renally as inactive metabolites; less than 1% is excreted unchanged. Acetic acid is rapidly metabolized via the tricarboxylic acid cycle and eliminated as carbon dioxide and water. Biliary/fecal elimination is negligible for both components.
Approximately 77% bound to albumin; minor binding to corticosteroid-binding globulin.
Hydrocortisone is approximately 90-95% bound to corticosteroid-binding globulin (CBG) and albumin. Acetic acid has negligible protein binding (<10%).
Vd ~0.8-1.0 L/kg; indicates extensive tissue distribution (crosses placenta, enters milk, penetrates CNS).
Hydrocortisone Vd is approximately 0.3-0.5 L/kg, indicating distribution into total body water. Acetic acid Vd is approximately 0.4 L/kg. Clinical meaning: limited tissue distribution; primarily remains in extracellular fluid.
Oral: 80-90%; IM: 80-100%; topical: negligible (systemic absorption <1% with intact skin).
Otic: Bioavailability is approximately 10-20% via the ear canal due to slow permeation through tympanic membrane; systemic absorption is minimal (<10% of applied dose). Oral: Not applicable; product is for otic use only.
No dose adjustment required for GFR <30 m L/min or dialysis; monitor for fluid retention.
No renal adjustment required as systemic absorption is negligible.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid or use with caution, reduce dose by 75%.
No hepatic adjustment required as systemic absorption is negligible.
0.08-0.3 mg/kg/day oral/IV/IM in 2-4 divided doses; asthma exacerbation: 0.6 mg/kg IV/IM (max 16 mg) once; croup: 0.6 mg/kg oral/IM once.
Same as adult: 5 drops into affected ear(s) 3-4 times daily. Safety and efficacy in children under 2 years not established.
Initiate at lowest effective dose; monitor for hyperglycemia, osteoporosis, and adrenal suppression; consider increased risk of fractures and infections.
No specific adjustment; use same adult dosing. Consider age-related skin thinning and potential for increased systemic absorption in cases of tympanic membrane perforation.
None required per FDA labeling.
None
Immunosuppression/increased infection risk,Adrenal suppression with prolonged use,Osteoporosis with long-term therapy,Hyperglycemia/diabetes exacerbation,Gastrointestinal perforation risk,Myopathy,Ocular effects (glaucoma, cataracts),Psychiatric disturbances
For otic use only; not for ophthalmic use,Prolonged use may result in overgrowth of non-susceptible organisms,Discontinue if sensitization or irritation occurs,Caution in patients with perforated tympanic membrane
Systemic fungal infections,Hypersensitivity to dexamethasone or components,Administration of live vaccines (relative contraindication),Idiopathic thrombocytopenic purpura (IM use in children)
Hypersensitivity to any component,Perforated tympanic membrane,Viral or fungal infections of the ear (except when used for fungal infections as indicated)
Limit high-sodium foods (processed snacks, canned soups) to reduce fluid retention. Avoid grapefruit and grapefruit juice as they increase dexamethasone levels via CYP3A4 inhibition. Increase potassium intake (bananas, spinach) if on loop diuretics.
No known food interactions. Avoid excessive alcohol as it may impair immune response.
First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppression, growth restriction, and altered brain development. Chronic use increases risk of preterm birth and low birth weight.
ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies in pregnant women. Animal reproduction studies with topical glucocorticoids have shown an increased risk of cleft palate and other malformations at high doses. Based on limited human data and low systemic exposure, use during pregnancy is generally considered low risk. However, as a precaution, avoid use in the first trimester unless clearly needed.
Dexamethasone is excreted into breast milk in low concentrations (M/P ratio approximately 0.5). Doses ≤15 mg/day are generally considered compatible with breastfeeding; higher doses require monitoring for infant adrenal suppression. Avoid breastfeeding within 4 hours of oral dose.
Systemic absorption after otic application is minimal. It is not known whether hydrocortisone or acetic acid is excreted in human milk. M/P ratio is not available. Concentrations in milk are likely negligible. Use is considered compatible with breastfeeding.
No routine dose adjustment required; however, increased clearance in pregnancy may necessitate higher doses for desired effect (e.g., fetal lung maturation). Consider lower doses for chronic conditions due to increased sensitivity. Taper gradually to avoid adrenal crisis.
No dose adjustment is necessary in pregnancy due to minimal systemic absorption. Pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety of this topical otic preparation.
Intravenous dexamethasone causes perineal itching due to phosphate esters; warn patients. Taper after prolonged use (>3 weeks) to avoid adrenal crisis. Single dose of 10 mg may elevate INR in warfarin patients via CYP3A4 inhibition. Monitor blood glucose and potassium during therapy.
ACETASOL HC (acetic acid 2%, hydrocortisone 1%) is used for otitis externa. Acetic acid restores acidic p H of ear canal, inhibiting bacterial and fungal growth. Hydrocortisone reduces inflammation and pruritus. Ensure tympanic membrane is intact before use due to risk of ototoxicity with corticosteroids in middle ear. Do not use for more than 7 days. Shake well before instillation.
Take with food or milk to reduce stomach upset.,Do not stop suddenly; follow taper schedule.,Report signs of infection (fever, sore throat) as steroid masks symptoms.,Avoid live vaccines during therapy.,Carry a steroid alert card if on long-term therapy.
Instill 3-4 drops into affected ear every 2-3 hours for 5-7 days.,Lie on side for 5 minutes after instillation to ensure coverage.,Avoid inserting cotton swabs or objects into the ear.,Discontinue if pain, worsening discharge, or rash occurs.,Do not use if ear drum is perforated or if you have a history of ear surgery.
"Dexamethasone, a potent corticosteroid, induces various cytochrome P450 (CYP) enzymes, including CYP2D6, which is primarily responsible for the metabolism of atomoxetine. Concurrent use can decrease atomoxetine metabolism, leading to elevated plasma concentrations and increased risk of atomoxetine-related adverse effects such as insomnia, dry mouth, nausea, and cardiovascular effects like hypertension and tachycardia. Close monitoring for atomoxetine toxicity is warranted when dexamethasone is coadministered."
"Dexamethasone, a potent corticosteroid, induces cytochrome P450 (CYP) 3A4 enzymes, which metabolize Vincristine, a vinca alkaloid chemotherapeutic agent. This induction increases Vincristine clearance, reducing its systemic exposure and potentially compromising its antineoplastic efficacy. Clinically, this may lead to suboptimal tumor response or require dose adjustments."
"Dexamethasone, a potent glucocorticoid, induces the expression of the enzyme 24-hydroxylase (CYP24A1), which accelerates the catabolism of calcitriol (1,25-dihydroxyvitamin D3) into inactive metabolites. This reduces the bioavailability and therapeutic efficacy of calcitriol, potentially leading to inadequate control of hypocalcemia in patients with chronic kidney disease or hypoparathyroidism. Clinically, this interaction may manifest as declining serum calcium levels or worsening bone mineral density despite calcitriol therapy."
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about DEXAMETHASONE vs ACETASOL HC, answered by our medical review team.
DEXAMETHASONE is a Corticosteroid that works by Agonist at glucocorticoid receptors, leading to altered gene expression and suppression of inflammatory mediators.. ACETASOL HC is a Otic Anti-infective with Corticosteroid that works by Acetic acid (otic solution) is antibacterial and antifungal; hydrocortisone is a corticosteroid that suppresses inflammation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between DEXAMETHASONE and ACETASOL HC depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of DEXAMETHASONE is: 0.5-24 mg/day oral, IV, IM in 2-4 divided doses; anti-inflammatory: 0.75-9 mg/day; multiple myeloma: 40 mg oral/IV once daily on days 1-4, 9-12, 17-20 every 28 days.. The standard adult dose of ACETASOL HC is: 5 drops into the affected ear(s) 3-4 times daily. Each drop contains 2% acetic acid and 1% hydrocortisone.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between DEXAMETHASONE and ACETASOL HC in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. DEXAMETHASONE is classified as Category D/X. First trimester: Associated with increased risk of cleft palate (approximately 0.1-0.3% absolute risk above baseline). Second and third trimesters: May cause fetal adrenal suppress. ACETASOL HC is classified as Category C. ACETASOL HC (hydrocortisone 1% and acetic acid 2%) is an otic solution. Systemic absorption following topical otic application is minimal. No adequate and well-controlled studies i. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.